Humphries Pharmaceutical Consulting (HPC) specializes in the field of pharmaceutical registration and is a pioneer in the registration Contract Research Organization (CRO) industry. We provide pharmaceutical registration services related to the regulatory frameworks in China and the United States.

Since 2015, with the opening of policies and the rapid flow of talents, funds, and technology, the level of technological innovation in the Chinese pharmaceutical industry has been increasing. Business development capabilities have also become more mature. From the early stages of simple licensing in, companies have gradually shifted to a combination of licensing in and licensing out, allowing them to quickly enter the market or secure financing through fast-follow strategies. Chinese pharmaceutical enterprises are making full use of the high-profit margins in foreign markets and the cost-effectiveness of domestic research and development, continuously optimizing their ecosystems. However, due to the relatively short duration of this internationalization development transformation and limited accumulated experience, various challenges are inevitably encountered in the process. Humphries utilizes its professional expertise to assist the pharmaceutical industry in navigating the complexities of business development and avoiding common pitfalls.